Drugs / Bifidobacterium viable pharmaceutics
Bifidobacterium viable pharmaceutics
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT02084004 | Nov 2015 → Apr 2018 | type 2 diabetes mellitus | Xijing Hospital | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT02082756 | Nov 2015 → Apr 2018 | prediabetes syndrome | Xijing Hospital | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bifidobacterium viable pharmaceutics | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02082756 ↗ |
| Modality | Other / unclassified | “Bifidobacterium, as a familiar probiotics, can modulate gut microbiota and improve glucose and lipid metabolism in animal experiments.” NCT02082756 ↗ |